Cargando…
Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY
BACKGROUND: Patients with cancer have an increased risk of VTE. We compared VTE rates and bleeding complications in 1) cancer patients receiving LMWH or UFH and 2) patients with or without cancer. METHODS: Acutely-ill, non-surgical patients ≥70 years with (n = 274) or without cancer (n = 2,965) rece...
Autores principales: | Haas, Sylvia, Schellong, Sebastian M, Tebbe, Ulrich, Gerlach, Horst-Eberhard, Bauersachs, Rupert, Melzer, Nima, Abletshauser, Claudia, Sieder, Christian, Bramlage, Peter, Riess, Hanno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161035/ https://www.ncbi.nlm.nih.gov/pubmed/21791091 http://dx.doi.org/10.1186/1471-2407-11-316 |
Ejemplares similares
-
Safety of heparin prophylaxis for venous thromboembolism in patients with neurotrauma
por: Puri, G, et al.
Publicado: (2010) -
A multi-center, prospective, open-label, 8-week study of certoparin for anticoagulation during maintenance hemodialysis – the membrane study
por: Dorsch, Oliver, et al.
Publicado: (2012) -
Colchicine as an adjunct to heparin for prophylaxis of venous thromboembolism in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021) -
Unfractionated heparin or low-molecular-weight heparin for venous thromboembolism prophylaxis after hepatic resection: A meta-analysis
por: Zhang, Wentao, et al.
Publicado: (2022) -
Effects of 8,000 IU aXa long-term prophylaxis with certoparin on the incidence of hyperkalemia in patients with coronary heart disease – a post-hoc analysis of the PARAT trial
por: Melzer, Nima, et al.
Publicado: (2014)